Oxford Cannabinoid Technologies Holdings PLC - holding company of Oxford Cannabinoid Technologies Ltd, a pharmaceutical group developing prescription cannabinoid medicines - Appoints Tim Corn as new chief medical officer, effective immediately. Read More
Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Announces that the Medicines & Healthcare Products Regulatory Agency and the Wales Research Ethics Committee have approved the company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. Participant enrolment will begin immediately, and the trial is expected to be completed during the third quarter. The trial is being funded entirely from OCTP's existing resources. Read More
Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Names Clarissa Sowemimo-Coker as permanent chief executive officer, effective immediately. She was named interim CEO in December, after having joined the firm over four years ago. Additionally, says its subsidiary Oxford Cannabinoid Technologies Ltd has renewed its Home Office licence, which permits OCT to supply Schedule 1 drugs for research purposes. Adds that progress towards the commencement of phase 1 clinical trial for its lead drug candidate, OCT461201, continues. Read More
(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Monday reported a widened half-year loss as research costs ballooned. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Says that on Wednesday, it submitted a combined clinical trials application to the UK Medicines & Healthcare products Regulatory Agency and the Wales Research Ethics Committee 2 for its lead programme OCT461201. Read More
Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical firm developing prescription cannabinoid medicines - Announces that Chief Executive John Lucas has decided to step down from his role "in order to pursue other business interests." Read More
Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Hires Paul Smalley as the new group finance director, effective from today. Says he will succeed Karen Lowe, who pans to stepd down from the board and leave the firm on October 31. Read More
(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Friday announced the reallocation of its existing budget, in the face of growing market uncertainty and a challenging macro-economic outlook. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday. Read More
(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Monday reported its loss widening as expenses increased. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday. Read More
(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Wednesday said it has entered a master service agreement regarding its neuropathy drug candidate with Pentrebach, Wales-based Simbec Research Ltd, which is part of Simbec-Orion Group Ltd. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Oxford Cannabinoid Technologies Holdings PLC - pharmaceutical company developing prescription cannabinoid medicines - Says results from recent study show that OCT461201 successfully reduces pain in a pre-clinical animal model of chemotherapy induced peripheral neuropathy induced by paclitaxel, a widely used chemotherapy agent. Two common symptoms of CIPN are pain caused by innocuous stimuli, like light touch and heat or cold. Says in the study, OCT461201 significantly reduced pain from both mechanical allodynia and thermal hyperalgesia compared to untreated animals. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More